Trump expands GLP‑1 Medicare access

GLP-1 drugs are the blockbuster weight-loss and diabetes medicines — Ozempic, Wegovy, Zepbound, that whole category. The stakes are huge because Medicare has millions of older patients who could want them, but the program has long been boxed in by a legal ban on covering drugs used specifically for weight loss. What changed this week is that Trump publicly said Medicare patients will get access starting July 1. That sounds like a brand-new promise, but turns out CMS had already built the mechanism: a temporary program called the Medicare GLP-1 Bridge. (usnews.com) ### What did Trump actually announce? On May 1, 2026, Trump said in The Villages, Florida, that the government is moving to make GLP-1 weight-loss and diabetes drugs available to seniors in Medicare from July 1. The headline version is simple — Medicare access is expanding. But the impor(usnews.com) that was already on the books. (usnews.com) ### So what is the GLP-1 Bridge? The Medicare GLP-1 Bridge is a short-term CMS demonstration. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026 through December 31, 2027. It runs outside the normal Part D coverage and payment flow, which matt(usnews.com)ay. CMS says one central processor will handle prior authorization, claims, and pharmacy payment in 2026. (cms.gov) ### Why not just cover these drugs normally? Because Medicare still has a statutory exclusion on drugs used specifically for weight loss. That is the core constraint. Part D can already cover GLP-1s when they are prescribed for other FDA-approved uses — things like type 2 diabetes, cardiovascular risk reduction, or slee(cms.gov)the doors.” It is “CMS found a temporary workaround.” (kff.org) ### Wasn’t there supposed to be a bigger program? Yes — BALANCE. CMS announced BALANCE in December 2025 as the broader model meant to expand access in Medicare Part D and Medicaid. Medicare Part D participation was supposed to start in 2027. But on April 21, 2026, CMS said BALANCE would not launch in Med(kff.org)looking rollout hit resistance, and the stopgap got longer. (cms.gov) ### Why did BALANCE stall? The catch is cost and insurer risk. KFF notes estimates that covering obesity drugs under Part D could cost Medicare roughly $25 billion to $35 billion over 10 years. Even with a reported $245 net price under the model, plans still may have worried that a flood of new use would swamp the savin(cms.gov)g reason CMS pulled back from the 2027 Part D launch and kept the Bridge outside normal plan risk. (kff.org) ### Who actually benefits first? Eligible Medicare Part D beneficiaries do — not every Medicare enrollee automatically, and not every GLP-1 for every reason. CMS has framed the Bridge as access to certain GLP-1 drugs for qualifying patients, with prior authorization and centralized claims handli(kff.org)ncrete than a vague promise of “better access.” (cms.gov) ### What should readers not overread here? Do not treat this as Congress permanently changing Medicare law. That has not happened. Do not assume every plan is suddenly covering Wegovy like a standard formulary drug. Also not true. And do not confuse existing GLP-1 coverage for diabetes or cardiovascular indications with(cms.gov)te, and a workaround structure. (kff.org) ### Bottom line Trump’s statement is real news, but the substance sits in CMS’s Bridge program. Medicare access to GLP-1s is expanding on July 1, 2026 — just not through the clean, permanent Part D overhaul many people assumed. (usnews.com)